Stock Market Reviews

INBX (Inhibrx Biosciences, Inc.) News

Get the latest news, insights, and market updates on INBX (Inhibrx Biosciences, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
  Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced that it will host a live webcast presentation on Thursday, October 23, 2025 at 1:30 p.m. Pacific Time to provide topline results from the registrational ChonDRAgon study investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosar
  Oct 22, 2025 - $INBX
• Owning 45% shares,institutional owners seem interested in Inhibrx Biosciences, Inc. (NASDAQ:INBX),
  Key Insights Institutions' substantial holdings in Inhibrx Biosciences implies that they have significant influence...
  Oct 11, 2025 - $INBX
• Insiders See US$5.42m Investment In Inhibrx Biosciences Jump Last Week
  NasdaqGS:INBX 1 Year Share Price vs Fair Value Explore Inhibrx Biosciences's Fair Values from the Community and select...
  Aug 15, 2025 - $INBX
• Inhibrx Reports Second Quarter 2025 Financial Results
  Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2025. Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials, with data readouts for each expected within the current year. Because the spi
  Aug 13, 2025 - $INBX
• Ligand Pharmaceuticals Stock Earns 84 RS Rating
  Ligand Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 84.
  Jul 17, 2025 - $INBX
• Liquidia Stock Gets Relative Strength Rating Lift
  A Relative Strength Rating upgrade for Liquidia shows improving technical performance. Will it continue?
  Jul 15, 2025 - $INBX
• Arcutis Biotherapeutics Stock Scores RS Rating Upgrade
  A Relative Strength Rating upgrade for Arcutis Biotherapeutics shows improving technical performance. Will it continue?
  Jul 10, 2025 - $INBX
• Inhibrx Reports First Quarter 2025 Financial Results
  Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2025. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials, with data readouts for each expected within the current year. Because the spin-off was accounted for a
  May 14, 2025 - $INBX
• Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President
  Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with two programs in clinical-stage development, today announced the departure of Dr. Brendan Eckelman, co-founder and Chief Scientific Officer (CSO) and the appointments of Dr. Carlos Bais and David Matly to CSO and President, respectively.
  Apr 1, 2025 - $INBX
• Inhibrx Biosciences Full Year 2024 Earnings: Beats Expectations
  Inhibrx Biosciences ( NASDAQ:INBX ) Full Year 2024 Results Key Financial Results Net income: US$1.69b (up from...
  Mar 19, 2025 - $INBX